| Literature DB >> 35291299 |
Hooman Parhizkar, Mark Fretz, Aurélie Laguerre, Jason Stenson, Richard L Corsi, Kevin G Van Den Wymelenberg, Elliott T Gall.
Abstract
Several studies suggest that far-field transmission (> 6 ft) explains the significant number of COVID-19 superspreading outbreaks. Therefore, quantitative evaluation of near- and far-field exposure to emissions from a source is key to better understanding human-to-human airborne infectious disease transmission and associated risks. In this study, we used an environmentally-controlled chamber to measure volatile organic compounds (VOCs) released from a healthy participant who consumed breath mints, which contained unique tracer compounds. Tracer measurements were made at 2.5 ft, 5 ft, 7.5 ft from the participant, as well as in the exhaust plenum of the chamber. We observed that 2.5 ft trials had substantially (~36-44%) higher concentrations than other distances during the first 20 minutes of experiments, highlighting the importance of the near-field relative to the far-field before virus-laden respiratory aerosol plumes are continuously mixed into the far-field. However, for the conditions studied, the concentrations of human-sourced tracers after 20 minutes and approaching the end of the 60-minute trials at 2.5 ft, 5 ft, and 7.5 ft were only ~18%, ~11%, and ~7.5% higher than volume-averaged concentrations, respectively. Our findings highlight the importance of far-field transmission of airborne pathogens including SARS-CoV-2, which need to be considered in public health decision making.Entities:
Year: 2022 PMID: 35291299 PMCID: PMC8923116 DOI: 10.21203/rs.3.rs-1437107/v2
Source DB: PubMed Journal: Res Sq
Figure 1Experimental setup, A) climate chamber, airflow distribution, as well as sampling location for each unique trial (modeled in Rhinoceros software), B) experimental procedure and the number of breath mints consumed by the participant for each trial.
Summary of all experiment trials
| Trials | Sampling probe distance from the participant’s mouth | Number of replicates | Sampling frequency (Hz) | Sampling duration (minutes) | Number of samples |
|---|---|---|---|---|---|
| A | 2.5 ft | 2 | 1 | 60 | 3600 |
| B | 5 ft | 2 | 1 | 60 | 3600 |
| C | 7.5 ft | 2 | 1 | 60 | 3600 |
| D | Exhaust | 2 | 1 | 60 | 3600 |
| E | Breath mint in a 250 ml glass container | 1 | 1 | 20 | 1200 |
| F | Breath mint exhaled into a 250 ml glass container | 1 | 1 | 20 | 1200 |
Comparison of the first and last minute of baseline period for five major compounds (paired t-test) for trials A-C (Table 1)
| Sampling distance from human source emitter (n = 60) | |||
|---|---|---|---|
| Compounds | 2.5ft | 5ft | 7.5ft |
|
| 0.0005(p = 0.92) | −0.005 (p = 0.32) | 0.0107 (p = 0.1) |
|
| 0.0086(p = 0.46) | 0.0189 (p = 0.35) | −0.0191 (p = 0.07) |
|
| 0.0015(p = 0.78) | 0.0015 (p = 0.76) | −0.0015 (p = 0.79) |
|
| 0.0704(p < 0.005) | −0.0556 (p < 0.001) | −0.04940 (p < 0.001) |
|
| 0.5982(p < 0.001) | −0.5913 (p < 0.001) | −0.3421 (p < 0.001) |
Figure 2A) Concentration of three target tracer compounds (menthol, menthone, and monoterpenes) in the headspace of a 250 mL glass chamber as a function the time when a breath mint is placed inside, B) Concentration of the three target compounds when the participant exhaled their breath once into the 250 mL chamber while consuming the breath mint.
Figure 3Comparison of 2.5, 5, and 7.5ft trials normalized by volume-averaged concentration.